R-CHOP looks viable as first line in follicular lymphomaNovember 15, 2018Follicular LymphomaB Cell Lymphoma
Sandoz won’t seek U.S. approval for rituximab biosimilarNovember 6, 2018Follicular LymphomaB Cell Lymphoma
Sandoz halts pursuit of U.S. approval for rituximab biosimilarNovember 5, 2018CLLFollicular LymphomaB Cell Lymphoma
Checkpoint inhibitor plus rituximab is active in non-Hodgkin lymphomaOctober 31, 2018Follicular LymphomaB Cell Lymphoma
Older age predicts mortality after alloHCT in NHL, but not relapseOctober 24, 2018Follicular LymphomaB Cell Lymphoma
Entospletinib falls short in relapsed/refractory DLBCLOctober 11, 2018Follicular LymphomaB Cell Lymphoma